GERMANY: BYK GULDEN, BAYER GASTROENTEROLOGY DEAL

Article Abstract:

In Germany, Konstanz-based Byk Gulden has acquired from Bayer AG the worldwide exclusive rights to the development and sales of a new active agent for the treatment of gastric and duodenal ulcers. It is believed that the agent called BY 377 might make monotherapy of helicobacter pylori possible. Byk Gulden is to start clinical tests in mid-2000. Bayer will continue to produce the agent.

Pharmaceutical Preparation Manufacturing, Strategic alliances, Digestive & Genito-Urinary Preps, Bayer AG, Byk Gulden

---

GERMANY: MORE CARBONIC ACID FROM RUHRCHEMIE

Article Abstract:

Ruhrchemie, a unit of Celanese, has raised the production of carbonic acid by 30% to 36,000 tpy at the factory in Oberhausen. The investment amounted to DM 5.5mn.

Production data, All Other Basic Inorganic Chemical Manufacturing, Inorganic Chemicals NEC, Inorganic compounds, Ruhrchemie AG

---

Similar abstracts:

• Abstracts: GERMANY: BAYER TO INCREASE TMP CAPACITY. GERMANY: BAYER TEST FOR HPV
• Abstracts: GERMANY: PHARMACEUTICAL FIRMS TEAM UP. GERMANY/US: SCHWARZ PHARMA, NEORX DROP PROJECT
• Abstracts: GERMANY: SKW TROSTBERG BOOSTS BIOTECH R&D. GERMANY: PARTNER SOUGHT FOR PLASTIC INVENTION

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.